Erlotinib (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Erlotinib" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

5nih.gov

4^th place

8^th place

3doi.org

2^nd place

5^th place

2drugs.com

399^th place

169^th place

2europa.eu

68^th place

28^th place

2harvard.edu

18^th place

31^st place

1termania.net

low place

34^th place

1fda.gov

447^th place

409^th place

1semanticscholar.org

11^th place

51^st place

1cancerresearchuk.org

8,489^th place

2,976^th place

1web.archive.org

1^st place

2^nd place

cancerresearchuk.org

https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/erlotinib/side-effects Arhivirano 2021-11-05 na Wayback Machine., vpogled: 5. 11. 2021.

doi.org

Balak MN, Gong Y, Riely GJ, in sod. (2006). »Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors«. Clin Cancer Res. 12 (1): 6494–501. doi:10.1158/1078-0432.CCR-06-1570. PMID 17085664.
Engelman JA, Zejnullahu K, Mitsudomi T, in sod. (2007). »MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling«. Science. 316 (5827): 1039–43. Bibcode:2007Sci...316.1039E. doi:10.1126/science.1141478. PMID 17463250. S2CID 23254145.
EBean J, Brennan C, Shih JY, in sod. (2007). »MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib«. PNAS. 104 (52): 20932–7. Bibcode:2007PNAS..10420932B. doi:10.1073/pnas.0710370104. PMC 2409244. PMID 18093943.

drugs.com

»Erlotinib (Tarceva) Use During Pregnancy«. Drugs.com. 1. november 2019. Pridobljeno 23. decembra 2019.
»Erlotinib Monograph for Professionals«. Drugs.com. Pridobljeno 12. novembra 2019.

europa.eu

ema.europa.eu

https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_sl.pdf Povzetek glavnih značilnosti zdravila Tarceva, vpogled: 4. 11. 2021.
https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva, vpogled: 4. 11. 2021.

fda.gov

accessdata.fda.gov

»Drug Approval Package: Tarceva (Erlotinib) NDA #021743«. U.S. Food and Drug Administration (FDA). 28. marec 2005. Pridobljeno 23. decembra 2019.

harvard.edu

ui.adsabs.harvard.edu

Engelman JA, Zejnullahu K, Mitsudomi T, in sod. (2007). »MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling«. Science. 316 (5827): 1039–43. Bibcode:2007Sci...316.1039E. doi:10.1126/science.1141478. PMID 17463250. S2CID 23254145.
EBean J, Brennan C, Shih JY, in sod. (2007). »MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib«. PNAS. 104 (52): 20932–7. Bibcode:2007PNAS..10420932B. doi:10.1073/pnas.0710370104. PMC 2409244. PMID 18093943.

nih.gov

pubmed.ncbi.nlm.nih.gov

Balak MN, Gong Y, Riely GJ, in sod. (2006). »Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors«. Clin Cancer Res. 12 (1): 6494–501. doi:10.1158/1078-0432.CCR-06-1570. PMID 17085664.
Engelman JA, Zejnullahu K, Mitsudomi T, in sod. (2007). »MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling«. Science. 316 (5827): 1039–43. Bibcode:2007Sci...316.1039E. doi:10.1126/science.1141478. PMID 17463250. S2CID 23254145.
EBean J, Brennan C, Shih JY, in sod. (2007). »MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib«. PNAS. 104 (52): 20932–7. Bibcode:2007PNAS..10420932B. doi:10.1073/pnas.0710370104. PMC 2409244. PMID 18093943.

dailymed.nlm.nih.gov

»Tarceva- erlotinib hydrochloride tablet«. DailyMed. 12. december 2018. Pridobljeno 23. decembra 2019.

ncbi.nlm.nih.gov

EBean J, Brennan C, Shih JY, in sod. (2007). »MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib«. PNAS. 104 (52): 20932–7. Bibcode:2007PNAS..10420932B. doi:10.1073/pnas.0710370104. PMC 2409244. PMID 18093943.

semanticscholar.org

api.semanticscholar.org

Engelman JA, Zejnullahu K, Mitsudomi T, in sod. (2007). »MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling«. Science. 316 (5827): 1039–43. Bibcode:2007Sci...316.1039E. doi:10.1126/science.1141478. PMID 17463250. S2CID 23254145.

termania.net

https://www.termania.net/slovarji/slovenski-medicinski-slovar/5514414/erlotinib?query=Erlotinib&SearchIn=All Slovenski medicinski e-slovar, vpogled: 4. 11. 2021.

web.archive.org

https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/erlotinib/side-effects Arhivirano 2021-11-05 na Wayback Machine., vpogled: 5. 11. 2021.